In short
This article discusses an ongoing clinical trial investigating the use of AAVB-081, a novel gene therapy treatment for Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa. AAVB-081 is an adeno-associated viral vector designed to deliver the MYO7A gene to the retina. The study aims to assess the safety, tolerability, and potential effectiveness of this innovative approach in treating this rare genetic eye disorder.
At a glance
- Study Type
- Phase 1/2 open-label, dose escalation, safety and efficacy study
- Drug Name
- AAVB-081 (Dual AAV8.MYO7A)
- Target Condition
- Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa
- Administration Method
- Subretinal injection
- Primary Objectives
- Assess safety, tolerability, and determine optimal dose
- Secondary Objective
- Evaluate effects on retinal anatomy and function
- Key Inclusion Criteria
- Adults 18-50 years old with molecular diagnosis of USH1B
- Key Exclusion Criteria
- History of retinal detachment, prior gene therapy, certain eye conditions
- Primary Endpoints
- Incidence and severity of adverse events, number of dose-limiting toxicities
What is AAVB-081?
AAVB-081 is an innovative gene therapy designed to treat a specific type of inherited eye disorder. It is classified as an advanced therapy medicinal product, which means it's a cutting-edge treatment that uses genetic material to address the root cause of a disease.
This therapy is also known by several other names, including:
- Dual AAV8.MYO7A
- AAV8.hMYO7A
- AAV8.5′MYO7A and AAV8.3′MYO7A
These names reflect the specific components and structure of the therapy.
Target Condition: Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa
AAVB-081 is being developed to treat a condition called Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa. This is a rare genetic disorder that affects both vision and hearing.
Retinitis pigmentosa is a group of inherited eye disorders that cause progressive vision loss. In people with USH1B, this condition is caused by mutations in a gene called MYO7A.
How AAVB-081 Works
AAVB-081 is a gene replacement therapy. It uses a modified virus called adeno-associated virus serotype 8 (AAV8) to deliver functional copies of the MYO7A gene to the retina, the light-sensitive tissue at the back of the eye.
The therapy consists of two parts:
- AAV8.5′MYO7A: This contains the first part of the MYO7A gene
- AAV8.3′MYO7A: This contains the second part of the MYO7A gene
Together, these two components aim to provide a complete, functional MYO7A gene to the cells in the retina, potentially slowing or stopping the progression of vision loss.
Clinical Trial Details
AAVB-081 is currently being studied in a Phase 1/2 clinical trial. This means it's in the early stages of testing in humans. The main goals of this trial are:
- To assess the safety and tolerability of AAVB-081 when injected into the space under the retina (subretinal administration)
- To determine the best dose that balances potential benefits with risks
- To evaluate how AAVB-081 affects the structure and function of the retina
This is an open-label study, which means both the researchers and participants know which treatment is being given. It also involves dose escalation, where different groups of participants receive increasing doses of the therapy to find the optimal amount.
Eligibility Criteria
To participate in this clinical trial, individuals must meet certain criteria. Some key requirements include:
- Being diagnosed with USH1B and having confirmed mutations in the MYO7A gene
- Being between 18 and 50 years old
- Having enough viable retinal cells for the treatment to potentially work
- Not having certain other eye conditions that could interfere with the treatment or its evaluation
There are also several conditions that would exclude someone from participating, such as a history of retinal detachment, poorly controlled diabetes, or previous participation in another gene therapy trial.
Safety and Monitoring
The safety of participants is a top priority in this clinical trial. The researchers will closely monitor for any side effects or adverse events. This includes:
- Regular physical examinations and vital sign checks
- Blood and urine tests
- Monitoring the immune system's response to the therapy
- Checking for the presence of the viral vector in blood and tears
- Comprehensive eye exams to track any changes in vision or eye structure
Potential Benefits
While it's important to note that the effectiveness of AAVB-081 is still being studied, the hope is that this therapy could potentially:
- Slow or stop the progression of vision loss in people with USH1B
- Improve retinal function
- Provide a long-lasting treatment option for this rare genetic condition
However, as with any experimental treatment, the actual benefits and risks will only be fully understood after thorough clinical testing.